Clinical Need
Cataracts are a loss of vision due to lens clouding.
If left untreated, cataracts can lead to blindness.
Current treatment options have limitations with visual side effects: glares, halos and artifacts.
Currently no solution mimics the natural ability of the eye to provide a full range of vision, from distance to near.
Solution
Atia Vision Modular Presbyopia Correcting Intraocular Lens (IOL)
Designed for true accommodation, aiming to restore the full range of vision
See How It Works
Watch the video to learn more about the Atia Vision Modular Presbyopia Correcting IOL
Company
Atia Vision is a portfolio company of Shifamed, LLC, a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.
The team at Atia Vision is committed to improving patient outcomes by developing a safe and controllable presbyopia correcting IOL that aims to restore the full range of functional vision in cataract patients, the largest segment of the ophthalmology market.3
Management Team
Board of Directors
Interested in joining the Atia Vision team?
Click here to see open positions with Atia Vision and Shifamed’s other portfolio companies.
Please submit your resume to hr@shifamed.com.
Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.
News
Atia Vision Closes Second Tranche of $20M in Series D Financing
CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.
Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting Intraocular Lens Technology
CAMPBELL, CA – September 11, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a novel modular presbyopiacorrecting intraocular lens (IOL), today announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France.
Atia Vision, A Shifamed Portfolio Company, Closes $20M in Series D Financing
CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.
Contact
Atia Vision, Inc.
550 Division Street
Campbell, CA 95008
info@atiavision.com
- World Health Organization, Visual Impairment and Blindness October 2017.
- YourSightMatters.com
- Market Scope 2017
Clinical Need
Cataracts are a loss of vision due to lens clouding.
If left untreated, cataracts can lead to blindness.
Current treatment options have limitations with visual side effects: glares, halos and artifacts.
Currently no solution mimics the natural ability of the eye to provide a full range of vision, from distance to near.
Solution
Atia Vision Modular Presbyopia Correcting Intraocular Lens (IOL)
Designed for true accommodation, aiming to restore the full range of vision
Seeking the Precision of True Accommodation
Accommodating base that is responsive to the ciliary muscles, simulating the natural mechanism of the eye
Aiming for a No-Compromise Treatment
Dual lens that addresses the needs of each patient and allows for future refractive corrections
Maintaining Clinical Workflow
Clinician control throughout a familiar conventional cataract procedure
See How It Works
Watch the video to learn more about the Atia Vision Modular Presbyopia Correcting IOL
Company
Atia Vision is a portfolio company of Shifamed, LLC, a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.
The team at Atia Vision is committed to improving patient outcomes by developing a safe and controllable presbyopia correcting IOL that aims to restore the full range of functional vision in cataract patients, the largest segment of the ophthalmology market.3
Management Team
Board of Directors
Interested in joining the Atia Vision team?
Click here to see open positions with Atia Vision and Shifamed’s other portfolio companies.
Please submit your resume to hr@shifamed.com.
Note: Principals only. No third-party referrals will be accepted without prior approval by Shifamed. As a general practice, Shifamed does not accept unsolicited resumes or placement information from any individual or agency that supplies candidates for a fee.
News
Atia Vision Closes Second Tranche of $20M in Series D Financing
CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.
Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting Intraocular Lens Technology
CAMPBELL, CA – September 11, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a novel modular presbyopiacorrecting intraocular lens (IOL), today announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France.
Atia Vision, A Shifamed Portfolio Company, Closes $20M in Series D Financing
CAMPBELL, CA – May 2, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular presbyopia-correcting accommodating intraocular lens, announced today initial closing of its committed $20M Series D preferred stock financing. Financing was led by Cormorant Asset Management, with participation by The Capital Partnership (TCP), AMED Ventures and Shangbay Capital. The financing will be used to advance Atia Vision’s clinical efforts.
Contact
- World Health Organization, Visual Impairment and Blindness October 2017.
- YourSightMatters.com
- Market Scope 2017